JP2024538015A5 - - Google Patents

Info

Publication number
JP2024538015A5
JP2024538015A5 JP2024520807A JP2024520807A JP2024538015A5 JP 2024538015 A5 JP2024538015 A5 JP 2024538015A5 JP 2024520807 A JP2024520807 A JP 2024520807A JP 2024520807 A JP2024520807 A JP 2024520807A JP 2024538015 A5 JP2024538015 A5 JP 2024538015A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
fdck
antidepressant
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520807A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538015A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/060011 external-priority patent/WO2023067505A1/en
Publication of JP2024538015A publication Critical patent/JP2024538015A/ja
Publication of JP2024538015A5 publication Critical patent/JP2024538015A5/ja
Pending legal-status Critical Current

Links

JP2024520807A 2021-10-18 2022-10-18 治療抵抗性うつ病を含むうつ病の治療のための２－フルオロデスクロロケタミン Pending JP2024538015A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163256728P 2021-10-18 2021-10-18
US63/256,728 2021-10-18
PCT/IB2022/060011 WO2023067505A1 (en) 2021-10-18 2022-10-18 2-fluorodeschloroketamine for treatment of depression, including treatment-resistant depression

Publications (2)

Publication Number Publication Date
JP2024538015A JP2024538015A (ja) 2024-10-18
JP2024538015A5 true JP2024538015A5 (https=) 2025-10-27

Family

ID=84178934

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520807A Pending JP2024538015A (ja) 2021-10-18 2022-10-18 治療抵抗性うつ病を含むうつ病の治療のための２－フルオロデスクロロケタミン

Country Status (8)

Country Link
US (1) US20250032429A1 (https=)
EP (1) EP4419092A1 (https=)
JP (1) JP2024538015A (https=)
KR (1) KR20240093579A (https=)
CN (1) CN118401239A (https=)
AU (1) AU2022374097A1 (https=)
CA (1) CA3233107A1 (https=)
WO (1) WO2023067505A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019094757A1 (en) * 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
CN119241381A (zh) * 2019-12-26 2025-01-03 吉尔伽美什制药公司 芳基环己基胺衍生物及其在精神障碍的治疗中的用途

Similar Documents

Publication Publication Date Title
JP2023100904A5 (https=)
Croft et al. Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks
JP2022504036A5 (https=)
JP2007511611A5 (https=)
JP2009538331A (ja) 抑うつ障害のための治療
RU2019143572A (ru) Композиции для лечения посттравматического стрессового расстройства
JP2011523949A5 (https=)
JP2015535290A5 (https=)
CN101198322A (zh) 用于治疗或预防抑郁症的新治疗组合
CZ20033267A3 (en) The use of enantiomeric pure escitalopram
JP2002516282A5 (https=)
US8735389B2 (en) Treating psychological conditions using muscarinic receptor M1 antagonists
JP2009520034A5 (https=)
RU2020125170A (ru) Композиции и способы улучшения биодоступности 5-гидрокситриптофана
JP2009542819A5 (https=)
JP2012036212A5 (https=)
Rubio et al. Reboxetine adjunct for partial or nonresponders to antidepressant treatment
JP2024538015A5 (https=)
JP2013079277A (ja) ムスカリン性受容体ｍ１拮抗薬による肥満の処置
JP2009542820A5 (https=)
Liu et al. Recent developments in monoamine reuptake inhibitors
JP2007505156A5 (https=)
JP2013032308A5 (https=)
Bodkin et al. Selegiline and other atypical monoamine oxidase inhibitors in depression
RU2455981C2 (ru) Лечение ожирения антагонистами мускаринового рецептора м1